Propanc Biopharma, Inc. Fair Value Disclosure
No disclosure content available
This topic may not be reported in the company's latest 10-K filing.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2022 | Sep 28, 2022 | Showing above |
| 2021 | Sep 28, 2021 | |
| 2020 | Oct 1, 2020 | |
| 2019 | Oct 15, 2019 | |
| 2018 | Sep 17, 2018 | |
| 2017 | Sep 28, 2017 | |
| 2016 | Sep 28, 2016 | |
| 2015 | Sep 30, 2015 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.